Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome

Hematological Oncology

Volumn 28, Issue 4, 2010, Pages 202-208

  Ferrara, Felicetto ^a   Palmieri, Salvatore ^a   Izzo, Tiziana ^a   Criscuolo, Clelia ^a   Riccardi, Cira ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Acute myeloid leukaemia; Cytogenetics; Myelodysplastic syndromes; Prognosis; Secondary

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; BUSULFAN; CYTARABINE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANDIDIASIS; CD34 SELECTION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FEVER; HUMAN; HYPOCALCEMIA; LEUKEMIA REMISSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYTARABINE; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 78650054483     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.943     Document Type: Article

References (48)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
2. Ferrara F, Pinto A. Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research. Rev Recent Clin Trials 2007; 2: 33-41.
3. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol 2008; 35: 430-438.
4. Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. Oncologist 2009; 14: 222-232.
5. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008; 66: 181-193.
6. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009; 37: 649-658.
7. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61-69.
8. Wheatley K, Brookes CL, Howman AJ, et al. United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598-605.
9. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
10. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908-1915.
11. Kuendgen A, Germing U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat Rev 2009; 35: 97-120.
12. Palmieri S, D'Arco AM, Celentano M, et al. An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. Ann Oncol 2006; 17: 1146-1151.
13. Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients>or=60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 2082-2090.
14. Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005; 16: 228-233.
15. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol 2007; 20: 29-37.
16. Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Predictive prognostic models for outcome. Cancer 2006; 106: 1090-1098.
17. Ferrara F, D'arco AM, Desimone MC, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 776-784.
18. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
19. Cheson B, Bennett J, Kopecky K, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
20. Ferrara F, Mele G, Palmieri S, et al. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematol Oncol 2009; 27: 198-202.
21. Ferrara F, Palmieri S, De Simone M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234-241.
22. WHO. Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva, 1979; 38.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
24. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 1(98): 1312-1320.
25. Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 2006; 43: 89-95.
26. Estey E. AML in older patients: Are we making progress? Best Pract Res Clin Haematol 2009; 22: 529-536.
27. Slovak M, Kopecky K, Cassileth P, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
28. Rizzieri DA, O'Brien JA, Broadwater G, et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009; 115: 2922-2929.
29. Ferrara F, Palmieri S, Pocali B, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002; 68: 203-209.
30. Bashey A, Liu L, Ihasz A, et al. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Leuk Res 2006; 30: 503-506.
31. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008; 113: 3181-3185.
32. Kim H, Park JH, Lee JH, et al. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study. Am J Hematol 2009; 84: 161-166.
33. Martin MG, Augustin KM, Uy GL, et al. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 2009; 84: 733-737.
34. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004; 103: 2908-2913.
35. Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 2780-2785.
36. Vidarsson B, Abonour R, Williams EC, et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 2001; 41: 321-331.
37. Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 1998; 4: 45-52.
38. Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs 2009; 18: 433-455.
39. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008; 35: 439-448.
40. Dombret H, Raffoux E, Gardin C. New insights in the management of elderly patients with acute myeloid leukemia. Curr Opin Oncol 2009; 21: 589-593.
41. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009; 113: 28-36.
42. Ferrara F, Viola A, Copia C, et al. Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. Hematol Oncol 2007; 25: 84-89.
43. Viola A, Falco C, D'Elia R, et al. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. Eur J Haematol 2007; 78: 41-47.
44. Ferrara F, Palmieri S, Celentano M, et al. Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leuk Lymphoma 2006; 47: 1593-1598.
45. Thomas X, Suciu S, Rio B, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007; 92: 389-396.
46. Herr AL, Labopin M, Blaise D, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007; 21: 129-135.
47. de Witte T, Suciu S, Brand R, et al. Autologous stem cell transplantation in myelodysplastic syndromes. Semin Hematol 2007; 44: 274-277.
48. Jung AS, Holman PR, Castro JE, et al. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 1306-1313.